Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 0.74
WST's Cash-to-Debt is ranked lower than
60% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.55 vs. WST: 0.74 )
Ranked among companies with meaningful Cash-to-Debt only.
WST' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 0.26 Max: N/A
Current: 0.74
Equity-to-Asset 0.67
WST's Equity-to-Asset is ranked higher than
60% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.61 vs. WST: 0.67 )
Ranked among companies with meaningful Equity-to-Asset only.
WST' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.35  Med: 0.49 Max: 0.67
Current: 0.67
0.35
0.67
Interest Coverage 29.62
WST's Interest Coverage is ranked lower than
55% of the 139 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 47.64 vs. WST: 29.62 )
Ranked among companies with meaningful Interest Coverage only.
WST' s Interest Coverage Range Over the Past 10 Years
Min: 5.4  Med: 7.99 Max: 29.62
Current: 29.62
5.4
29.62
Piotroski F-Score: 7
Altman Z-Score: 10.03
Beneish M-Score: -2.53
WACC vs ROIC
8.92%
15.24%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 14.86
WST's Operating Margin % is ranked higher than
77% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.03 vs. WST: 14.86 )
Ranked among companies with meaningful Operating Margin % only.
WST' s Operating Margin % Range Over the Past 10 Years
Min: 8.21  Med: 10.07 Max: 14.86
Current: 14.86
8.21
14.86
Net Margin % 11.88
WST's Net Margin % is ranked higher than
76% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.21 vs. WST: 11.88 )
Ranked among companies with meaningful Net Margin % only.
WST' s Net Margin % Range Over the Past 10 Years
Min: 5.91  Med: 6.91 Max: 11.88
Current: 11.88
5.91
11.88
ROE % 16.24
WST's ROE % is ranked higher than
79% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.23 vs. WST: 16.24 )
Ranked among companies with meaningful ROE % only.
WST' s ROE % Range Over the Past 10 Years
Min: 9.65  Med: 13.52 Max: 17.69
Current: 16.24
9.65
17.69
ROA % 10.65
WST's ROA % is ranked higher than
82% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.67 vs. WST: 10.65 )
Ranked among companies with meaningful ROA % only.
WST' s ROA % Range Over the Past 10 Years
Min: 5.09  Med: 6.34 Max: 10.65
Current: 10.65
5.09
10.65
ROC (Joel Greenblatt) % 23.29
WST's ROC (Joel Greenblatt) % is ranked higher than
68% of the 195 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 12.30 vs. WST: 23.29 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
WST' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 12.75  Med: 17.48 Max: 23.29
Current: 23.29
12.75
23.29
3-Year Revenue Growth Rate 1.60
WST's 3-Year Revenue Growth Rate is ranked lower than
59% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. WST: 1.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
WST' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -2.9  Med: 5.1 Max: 17.8
Current: 1.6
-2.9
17.8
3-Year EBITDA Growth Rate 3.30
WST's 3-Year EBITDA Growth Rate is ranked lower than
53% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. WST: 3.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
WST' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -20.3  Med: 6.5 Max: 39.8
Current: 3.3
-20.3
39.8
3-Year EPS without NRI Growth Rate 6.80
WST's 3-Year EPS without NRI Growth Rate is ranked higher than
60% of the 131 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.20 vs. WST: 6.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
WST' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -38.6  Med: 7.1 Max: 73.1
Current: 6.8
-38.6
73.1
GuruFocus has detected 4 Warning Signs with West Pharmaceutical Services Inc $WST.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» WST's 30-Y Financials

Financials (Next Earnings Date: 2017-10-27 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:NYSE:STE, NYSE:HRC, OTCPK:SAUHY, OTCPK:GNGBF, NAS:ICUI, NYSE:CMD, NYSE:RMD, NAS:PODD, OTCPK:ANSLF, NYSE:COO, NYSE:HAE, NAS:MMSI, NYSE:HYH, OTCPK:OCPNY, OTCPK:TOPCF, NAS:NXTM, NYSE:GKOS, NAS:NVCR, OTCPK:PLHNF, NAS:HOLX » details
Traded in other countries:WPS.Germany,
Headquarter Location:USA
West Pharmaceutical Services Inc develops, manufactures and sells packaging components and systems for injectable drug delivery, including stoppers and seals for vials, closures and other components used in syringe, and prefillable syringe components.

West Pharmaceutical Services Inc was incorporated under the laws of the Commonwealth of Pennsylvania on July 27, 1923. The Company is a manufacturer of components and systems for the packaging and delivery of injectable drugs as well as delivery system components for the pharmaceutical, healthcare and consumer products industries. Majority of its business is conducted in healthcare markets. Its reportable segments are Proprietary Products and Contract-Manufactured Products. Proprietary Products offers proprietary packaging, containment, and drug delivery products. The packaging products include stoppers and seals for injectable packaging systems, which are designed to help ensure drug compatibility and stability, while also supporting operational efficiency. Proprietary Products also offers syringe and cartridge components, including custom solutions for the specific needs of injectable drug applications. The Company competes with several companies across its product lines. Competition is based mainly on product design and performance, although total cost is becoming increasingly important as pharmaceutical companies continue with aggressive cost control programs across their entire operations. The design, development, manufacturing, marketing, and labeling of certain of the Company's products and its customer's products that incorporate its products are subject to regulation by governmental authorities in the United States, Europe, and other countries, including the FDA and the European Medicines Agency.

Guru Investment Theses on West Pharmaceutical Services Inc

Baron Asset Fund Comments on West Pharmaceutical Services - Jan 30, 2017

Shares of West Pharmaceutical Services, Inc. (NYSE:WST), a manufacturer of packaging components and delivery devices for injectable drugs, gained after reporting impressive quarterly financial results. Management provided solid guidance for 2017 and reaffirmed its goals for strong growth through 2020. We continue to believe that West can double its earnings over the next five years, driven by sales of higher margin packaging components and proprietary products to the pharmaceutical and biotechnology industries.



From Barron Asset Fund fourth quarter 2016 commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on West Pharmaceutical Services - Apr 26, 2016

West Pharmaceutical Services, Inc. (NYSE:WST) manufactures components and systems for the packaging and delivery of injectable drugs. West’s shares gained during the quarter after reporting strong financial results and providing solid earnings guidance for 2016. West’s products are frequently “designed in” as part of the regulatory approval process for its clients’ drugs, which makes it quite difficult for West’s products to be displaced throughout a drug’s lifecycle. There is a substantial development pipeline of injectable biologic drugs, and we believe this will allow West to experience double-digit growth rates in its main market for at least the next several years. We also believe that West will benefit from the increased sale of high-margin proprietary products, including newly-developed plastic syringes and wearable injectors for a new generation of high volume, high viscosity drugs. As a result, we believe that company has the potential to double its earnings during the next five years.



From Baron Asset Funds' first quarter 2016 commentary.



Check out Ron Baron latest stock trades

Top Ranked Articles about West Pharmaceutical Services Inc

West Elects New Director to the Board
West to Present on Biologics Trends at InnoPack Pharma Confex
Insiders Roundup: Facebook, General Electric, Aetna The largest insider trades of the week
The GuruFocus All-in-One Screener can be used to find insider trades from the past week. Under the Insiders tab, change the settings for All Insider Buying to “$200,000+,” the duration to “March 2017” and All Insider Sales to “$5,000,000+.” Read more...
West Announces Quarterly Dividend and Participation in Upcoming Investor Conferences
West Highlights Company Scientific and Regulatory Expertise at Notable Industry Meetings
West Announces First-Quarter 2017 Results
West to Host First-Quarter 2017 Conference Call
Baron Asset Fund Comments on West Pharmaceutical Services Guru stock highlight
Shares of West Pharmaceutical Services, Inc. (NYSE:WST), a manufacturer of packaging components and delivery devices for injectable drugs, gained after reporting impressive quarterly financial results. Management provided solid guidance for 2017 and reaffirmed its goals for strong growth through 2020. We continue to believe that West can double its earnings over the next five years, driven by sales of higher margin packaging components and proprietary products to the pharmaceutical and biotechnology industries. Read more...

Ratios

vs
industry
vs
history
PE Ratio 39.64
WST's PE Ratio is ranked lower than
69% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.49 vs. WST: 39.64 )
Ranked among companies with meaningful PE Ratio only.
WST' s PE Ratio Range Over the Past 10 Years
Min: 12.28  Med: 23.2 Max: 64.85
Current: 39.64
12.28
64.85
Forward PE Ratio 38.31
WST's Forward PE Ratio is ranked lower than
74% of the 39 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.62 vs. WST: 38.31 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 39.64
WST's PE Ratio without NRI is ranked lower than
70% of the 125 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.49 vs. WST: 39.64 )
Ranked among companies with meaningful PE Ratio without NRI only.
WST' s PE Ratio without NRI Range Over the Past 10 Years
Min: 12.28  Med: 23.13 Max: 64.85
Current: 39.64
12.28
64.85
Price-to-Owner-Earnings 83.66
WST's Price-to-Owner-Earnings is ranked lower than
81% of the 84 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 33.25 vs. WST: 83.66 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
WST' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 19.16  Med: 39.72 Max: 173.32
Current: 83.66
19.16
173.32
PB Ratio 6.03
WST's PB Ratio is ranked lower than
75% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.28 vs. WST: 6.03 )
Ranked among companies with meaningful PB Ratio only.
WST' s PB Ratio Range Over the Past 10 Years
Min: 1.74  Med: 2.93 Max: 6.21
Current: 6.03
1.74
6.21
PS Ratio 4.71
WST's PS Ratio is ranked lower than
62% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.25 vs. WST: 4.71 )
Ranked among companies with meaningful PS Ratio only.
WST' s PS Ratio Range Over the Past 10 Years
Min: 1.02  Med: 1.6 Max: 4.84
Current: 4.71
1.02
4.84
Price-to-Free-Cash-Flow 105.47
WST's Price-to-Free-Cash-Flow is ranked lower than
87% of the 71 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.86 vs. WST: 105.47 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
WST' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 18.49  Med: 47.62 Max: 381.09
Current: 105.47
18.49
381.09
Price-to-Operating-Cash-Flow 30.42
WST's Price-to-Operating-Cash-Flow is ranked lower than
69% of the 93 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.73 vs. WST: 30.42 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
WST' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.55  Med: 12.04 Max: 31.38
Current: 30.42
7.55
31.38
EV-to-EBIT 31.03
WST's EV-to-EBIT is ranked lower than
71% of the 121 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.50 vs. WST: 31.03 )
Ranked among companies with meaningful EV-to-EBIT only.
WST' s EV-to-EBIT Range Over the Past 10 Years
Min: 11.2  Med: 19 Max: 53.3
Current: 31.03
11.2
53.3
EV-to-EBITDA 22.20
WST's EV-to-EBITDA is ranked lower than
64% of the 135 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.46 vs. WST: 22.20 )
Ranked among companies with meaningful EV-to-EBITDA only.
WST' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.6  Med: 12.05 Max: 27.6
Current: 22.2
7.6
27.6
PEG Ratio 5.69
WST's PEG Ratio is ranked lower than
74% of the 66 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.81 vs. WST: 5.69 )
Ranked among companies with meaningful PEG Ratio only.
WST' s PEG Ratio Range Over the Past 10 Years
Min: 1.01  Med: 2.19 Max: 50.27
Current: 5.69
1.01
50.27
Shiller PE Ratio 66.61
WST's Shiller PE Ratio is ranked lower than
71% of the 49 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 50.38 vs. WST: 66.61 )
Ranked among companies with meaningful Shiller PE Ratio only.
WST' s Shiller PE Ratio Range Over the Past 10 Years
Min: 19.08  Med: 34.79 Max: 68.7
Current: 66.61
19.08
68.7
Current Ratio 2.54
WST's Current Ratio is ranked lower than
52% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.67 vs. WST: 2.54 )
Ranked among companies with meaningful Current Ratio only.
WST' s Current Ratio Range Over the Past 10 Years
Min: 1.37  Med: 2.1 Max: 3.1
Current: 2.54
1.37
3.1
Quick Ratio 1.72
WST's Quick Ratio is ranked lower than
51% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.73 vs. WST: 1.72 )
Ranked among companies with meaningful Quick Ratio only.
WST' s Quick Ratio Range Over the Past 10 Years
Min: 0.85  Med: 1.51 Max: 2.28
Current: 1.72
0.85
2.28
Days Inventory 71.69
WST's Days Inventory is ranked higher than
85% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 128.19 vs. WST: 71.69 )
Ranked among companies with meaningful Days Inventory only.
WST' s Days Inventory Range Over the Past 10 Years
Min: 52.45  Med: 64.65 Max: 71.69
Current: 71.69
52.45
71.69
Days Sales Outstanding 53.46
WST's Days Sales Outstanding is ranked higher than
67% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.12 vs. WST: 53.46 )
Ranked among companies with meaningful Days Sales Outstanding only.
WST' s Days Sales Outstanding Range Over the Past 10 Years
Min: 41.76  Med: 47.63 Max: 53.46
Current: 53.46
41.76
53.46
Days Payable 37.86
WST's Days Payable is ranked lower than
65% of the 152 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 50.69 vs. WST: 37.86 )
Ranked among companies with meaningful Days Payable only.
WST' s Days Payable Range Over the Past 10 Years
Min: 29.33  Med: 39.47 Max: 46.32
Current: 37.86
29.33
46.32

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.53
WST's Dividend Yield % is ranked lower than
80% of the 158 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.17 vs. WST: 0.53 )
Ranked among companies with meaningful Dividend Yield % only.
WST' s Dividend Yield % Range Over the Past 10 Years
Min: 0.51  Med: 1.19 Max: 2.01
Current: 0.53
0.51
2.01
Dividend Payout Ratio 0.21
WST's Dividend Payout Ratio is ranked higher than
75% of the 92 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.30 vs. WST: 0.21 )
Ranked among companies with meaningful Dividend Payout Ratio only.
WST' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.21  Med: 0.27 Max: 0.35
Current: 0.21
0.21
0.35
3-Year Dividend Growth Rate 8.40
WST's 3-Year Dividend Growth Rate is ranked higher than
50% of the 64 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.40 vs. WST: 8.40 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
WST' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 1  Med: 7 Max: 13.7
Current: 8.4
1
13.7
Forward Dividend Yield % 0.54
WST's Forward Dividend Yield % is ranked lower than
83% of the 137 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.27 vs. WST: 0.54 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.75
WST's 5-Year Yield-on-Cost % is ranked lower than
74% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.44 vs. WST: 0.75 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
WST' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.72  Med: 1.68 Max: 2.85
Current: 0.75
0.72
2.85
3-Year Average Share Buyback Ratio -1.40
WST's 3-Year Average Share Buyback Ratio is ranked higher than
64% of the 131 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -4.20 vs. WST: -1.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
WST' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -4.3  Med: -1 Max: 4.8
Current: -1.4
-4.3
4.8

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 79.98
WST's Price-to-Net-Current-Asset-Value is ranked lower than
93% of the 121 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.00 vs. WST: 79.98 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
WST' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 68.01  Med: 142.45 Max: 2007.33
Current: 79.98
68.01
2007.33
Price-to-Tangible-Book 6.75
WST's Price-to-Tangible-Book is ranked lower than
65% of the 158 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.75 vs. WST: 6.75 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
WST' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.2  Med: 2.8 Max: 6.87
Current: 6.75
1.2
6.87
Price-to-Intrinsic-Value-Projected-FCF 4.72
WST's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
86% of the 86 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.24 vs. WST: 4.72 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
WST' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.97  Med: 2.05 Max: 4.76
Current: 4.72
0.97
4.76
Price-to-Intrinsic-Value-DCF (Earnings Based) 3.43
WST's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
68% of the 22 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.12 vs. WST: 3.43 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 2.95
WST's Price-to-Median-PS-Value is ranked lower than
95% of the 174 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.12 vs. WST: 2.95 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
WST' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.38  Med: 0.73 Max: 2.97
Current: 2.95
0.38
2.97
Price-to-Peter-Lynch-Fair-Value 7.22
WST's Price-to-Peter-Lynch-Fair-Value is ranked lower than
96% of the 49 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.46 vs. WST: 7.22 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
WST' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.54  Med: 1.67 Max: 8.3
Current: 7.22
0.54
8.3
Price-to-Graham-Number 3.45
WST's Price-to-Graham-Number is ranked lower than
67% of the 95 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.52 vs. WST: 3.45 )
Ranked among companies with meaningful Price-to-Graham-Number only.
WST' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.96  Med: 1.59 Max: 3.79
Current: 3.45
0.96
3.79
Earnings Yield (Greenblatt) % 3.23
WST's Earnings Yield (Greenblatt) % is ranked higher than
57% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.66 vs. WST: 3.23 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
WST' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.9  Med: 5.3 Max: 8.9
Current: 3.23
1.9
8.9
Forward Rate of Return (Yacktman) % 6.32
WST's Forward Rate of Return (Yacktman) % is ranked lower than
63% of the 95 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.07 vs. WST: 6.32 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
WST' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -3.7  Med: 10 Max: 22.1
Current: 6.32
-3.7
22.1

More Statistics

Revenue (TTM) (Mil) $1,534.70
EPS (TTM) $ 2.42
Beta1.17
Short Percentage of Float1.96%
52-Week Range $70.17 - 99.91
Shares Outstanding (Mil)73.55

Analyst Estimate

Dec17
Revenue (Mil $)
EPS ($) 2.52
EPS without NRI ($) 2.52
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for WST

Headlines

Articles On GuruFocus.com
West Elects New Director to the Board Jun 01 2017 
West to Present on Biologics Trends at InnoPack Pharma Confex May 30 2017 
Insiders Roundup: Facebook, General Electric, Aetna May 19 2017 
West Announces Quarterly Dividend and Participation in Upcoming Investor Conferences May 15 2017 
West Highlights Company Scientific and Regulatory Expertise at Notable Industry Meetings May 03 2017 
West Announces First-Quarter 2017 Results Apr 27 2017 
West to Host First-Quarter 2017 Conference Call Apr 13 2017 
Baron Asset Fund Comments on West Pharmaceutical Services Jan 30 2017 
Baron Asset Fund 4th Quarter Shareholder Letter Jan 30 2017 
Baron Funds Comments on West Pharmaceutical Services Apr 26 2016 

More From Other Websites
3 Best Healthcare Dividend Stocks of the 21st Century (So Far) Jun 24 2017
West Elects New Director to the Board Jun 01 2017
West to Present on Biologics Trends at InnoPack Pharma Confex May 30 2017
West Announces Quarterly Dividend and Participation in Upcoming Investor Conferences May 15 2017
ETFs with exposure to West Pharmaceutical Services, Inc. : May 9, 2017 May 09 2017
West Pharmaceutical Services, Inc. :WST-US: Earnings Analysis: Q1, 2017 By the Numbers : May 8, 2017 May 08 2017
West Highlights Company Scientific and Regulatory Expertise at Notable Industry Meetings May 03 2017
Edited Transcript of WST earnings conference call or presentation 27-Apr-17 1:00pm GMT Apr 29 2017
West Pharmaceutical Services, Inc.: Price momentum supported by strong fundamentals Apr 28 2017
Why West Pharmaceutical Services Is Rising Today Apr 27 2017
West Pharmaceutical tops Street 1Q forecasts Apr 27 2017
West Announces First-Quarter 2017 Results Apr 27 2017
Medical Product Stocks' Earnings on Apr 27: ZBH, RMD & More Apr 26 2017
West Pharmaceutical Services, Inc. : WST-US: Dividend Analysis : April 19th, 2017 (record date) : By... Apr 19 2017
West to Host First-Quarter 2017 Conference Call Apr 13 2017
ETFs with exposure to West Pharmaceutical Services, Inc. : April 7, 2017 Apr 07 2017
West Pharmaceutical Services, Inc. : WST-US: Dividend Analysis : January 18th, 2017 (record date) :... Mar 16 2017
West Pharmaceutical Services, Inc. :WST-US: Earnings Analysis: 2016 By the Numbers : February 21,... Feb 21 2017
West Pharmaceutical Services, Inc. :WST-US: Earnings Analysis: Q4, 2016 By the Numbers : February... Feb 17 2017
Edited Transcript of WST earnings conference call or presentation 16-Feb-17 2:00pm GMT Feb 16 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}